1. MACE: Death, MI or TLR at 5 years
Gamma-1: Five Year Follow-up Vascular Gamma Brachytherapy vs placebo for In-stent Restenosis in Native Coronary Lesions
MACE: Death, MI or TLR at 5 years
p = 0.380
p = 0.254
p = 0.064 %
p = 1.000

2. Gamma-1: Five Year Follow-up
Among patients treated with gamma brachytherapy or placebo for in-stent restenosis in native coronary lesions, there were no statistically significant differences in MACE, TLR, or TVR at five-years.
The risk of recurrent MI tended to be higher among patients treated with gamma brachytherapy (p=0.06)
While there was a clinical benefit at 9 months for gamma brachytherapy, these five-year results demonstrate no significant benefit of gamma brahcytherapy consistent with a “late catch-up” or delay in restenosis among these patients.